New assay detects patients’ resistance to antimalarial drugs from a drop of blood

New technique simplifies detection of single nucleotide polymorphisms and can provide critically important information quickly, even in resource limiting facilities, reports The Journal of Molecular Diagnostics


Philadelphia, June 13, 2019

Antimalarial drugs appear to follow a typical pattern, with early effectiveness eventually limited by the emergence of drug resistance. A report in The Journal of Molecular Diagnostics, published by Elsevier, describes a new assay using whole blood that simplifies the genetic analysis of malarial parasites by completely eliminating processing steps. This provides rapid access to critical information associated with resistance to antimalarials at the point of care, avoiding the time, expense and effort of having the sample sent to a central laboratory, and allowing clinicians to quickly re-evaluate treatment options.

Blood contains a wealth of genetic information, but currently must undergo significant processing to remove components that interfere with molecular analyses. Although an exciting prospect, gathering genetic information from a single drop of blood has proved elusive. This study, which analyzed a single mutation in a malaria parasite, provides the first steps to do just that: a drop of blood can be used directly, without any additional processing, to assess a range of genetic data.

“Monitoring of antimalarial resistance is important to prevent its further spread, but the available options for assessing resistance are less than ideal for field settings. Although molecular detection is perhaps the most efficient method, it is also the most complex because it requires DNA extraction and PCR instrumentation,” noted co-lead investigator Mindy Leelawong, PhD, Research Assistant Professor of Biomedical Engineering, Vanderbilt University, Nashville, TN, USA. “Our strategy eliminates the most time- and labor-intensive step: DNA extraction. By creating a procedure that overcomes the obstacles presented by blood, we have developed a simple method to quickly identify mutations associated with drug resistance. As a consequence, higher throughput testing and more rapid sample-to-result turnaround will be possible.”

“To mitigate the inhibition by blood components, we redesigned the molecular tools used for DNA analysis. We utilized reporter dyes that are more optically compatible with blood, which were combined with a specific type of DNA subunit to accurately pinpoint mutations. The end result is an assay in which blood is directly added to a reaction tube to detect mutations associated with antimalarial drug resistance,” explained co-lead investigator Frederick R. Haselton, PhD, of the Departments of Biomedical Engineering and Chemistry at Vanderbilt University.

Dr. Leelawong and Dr. Haselton, along with co-lead investigator David W. Wright, PhD, of the Department of Chemistry at Vanderbilt, anticipate that the technique can be modified for assessing resistance to artemisinin, the current first-line therapy for malarial infection, or future drugs as they become available. The technique may also become a platform for evaluating other molecular targets found in blood.

The technology detailed in this study offers a potential platform to manage the spread of drug resistance on the ground. According to Dr. Wright, “These drug-resistant parasites must not spread; we know from previous generations of drugs that the consequences can be catastrophic. To prevent further spread, the geographic location of drug-resistant parasites must be known.”

Malaria is a serious, sometimes fatal disease caused by a parasite that commonly infects a certain type of mosquito that feeds on humans and infects red blood cells. People who contract malaria typically become very sick with high fevers, shaking chills, and flu-like illness. According to the World Malaria Report 2018, there were 219 million cases of malaria globally in 2017 resulting in 435,000 malaria deaths. Although antimalarial drugs are often effective, outcomes are worse for those who are drug resistant.

---

Notes for editors
The article is “Detection of Single Nucleotide Polymorphism Markers of Antimalarial Drug Resistance Directly from Whole Blood,” by Mindy Leelawong, Nicholas M. Adams, William E. Gabella, David W. Wright, and Frederick R. Haselton(https://doi.org/10.1016/j.jmoldx.2019.02.004). It will appear in The Journal of Molecular Diagnostics, volume 21, issue 4 (July 2019) published by Elsevier.

Full text of this study is available to credentialed journalists upon request; contact Eileen Leahy at +1 732 238 3628 or jmdmedia@elsevier.com. Journalists wishing to interview the authors should contact Heidi Hall at +1 615 322 6614 or heidi.hall@vanderbilt.edu.

This work was supported by NIH STTR grant (R42 HG009470-02) and the NIH-funded Vanderbilt Network for Innovation in Global Health Technologies (D43TW009348).

About The Journal of Molecular Diagnostics
The Journal of Molecular Diagnostics
, the official publication of the Association for Molecular Pathology, co-owned by the American Society for Investigative Pathology, and published by Elsevier, seeks to publish high quality original papers on scientific advances in the translation and validation of molecular discoveries in medicine into the clinical diagnostic setting, and the description and application of technological advances in the field of molecular diagnostic medicine. The editors welcome review articles that contain: novel discoveries or clinicopathologic correlations, including studies in oncology, infectious diseases, inherited diseases, predisposition to disease, or the description of polymorphisms linked to disease states or normal variations; the application of diagnostic methodologies in clinical trials; or the development of new or improved molecular methods for diagnosis or monitoring of disease or disease predisposition. jmd.amjpathol.org

About Elsevier
Elsevier is a global information analytics business that helps scientists and clinicians to find new answers, reshape human knowledge, and tackle the most urgent human crises. For 140 years, we have partnered with the research world to curate and verify scientific knowledge. Today, we’re committed to bringing that rigor to a new generation of platforms. Elsevier provides digital solutions and tools in the areas of strategic research management, R&D performance, clinical decision support, and professional education; including ScienceDirect, Scopus, SciVal, ClinicalKey and Sherpath. Elsevier publishes over 2,500 digitized journals, including The Lancet and Cell, 39,000 e-book titles and many iconic reference works, including Gray's Anatomy. Elsevier is part of RELX Group, a global provider of information and analytics for professionals and business customers across industries. www.elsevier.com

Media contacts
Eileen Leahy
Elsevier
+1 732 238 3628
jmdmedia@elsevier.com

Chhavi Chauhan, PhD, Director of Scientific Outreach
The Journal of Molecular Diagnostics
+1 240 283 9724
cchauhan@asip.org